Maria Javier Ramirez

Dr. Maria Javier Ramirez

Department of Pharmacology and Toxicology, Faculty of Pharmacy and Nutrition, Universidad de Navarra, Pamplona, Spain
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
MJManuel H. Janeiro
Manuel H. Janeiro
Maria Javier RamirezMaria Javier Ramirez
Maria Javier Ramirez
Fermín I. MilagroFermín I. Milagro
Fermín I. Milagro
JMJ. Alfredo Martinez
J. Alfredo Martinez
MSMaite Solas
Maite Solas
Trimethylamine N-oxide (TMAO) is a molecule generated from choline, betaine, and carnitine via gut microbial metabolism. The plasma level of TMAO is determined by several factors including diet, gut microbial flora, drug administration and liver flavin monooxygenase activity. In humans, recent clinical studies evidence a positive correlation between elevated plasma levels of TMAO and an increased risk for major adverse cardiovascular events. A direct correlation between increased TMAO levels and neurological disorders has been also hypothesized. Several therapeutic strategies are being explored to reduce TMAO levels, including use of oral broad spectrum antibiotics, promoting the growth of bacteria that use TMAO as substrate and the development of target-specific molecules. Despite the accumulating evidence, it is questioned whether TMAO is the mediator of a bystander in the disease process. Thus, it is important to undertake studies to establish the role of TMAO in human health and disease. In this article, we reviewed dietary sources and metabolic pathways of TMAO, as well as screened the studies suggesting possible involvement of TMAO in the etiology of cardiovascular and neurological disorders, underlying the importance of TMAO mediating inflammatory processes. Finally, the potential utility of TMAO as therapeutic target is also analyzed.

1 April 2007 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
BABárbara Aisa
Bárbara Aisa
RTRosa Tordera
Rosa Tordera
BLBerta Lasheras
Berta Lasheras
JRJoaquín Del Río
Joaquín Del Río
Maria Javier RamirezMaria Javier Ramirez
Maria Javier Ramirez

12 January 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
RYRamon Yarza
Ramon Yarza
SVSilvia Vela
Silvia Vela
MSMaite Solas
Maite Solas
Maria Javier RamirezMaria Javier Ramirez
Maria Javier Ramirez
C-Jun N-terminal kinases (JNKs) are a family of protein kinases that play a central role in stress signaling pathways implicated in gene expression, neuronal plasticity, regeneration, cell death and regulation of cellular senescence. It has been shown that there is a JNK pathway activation after exposure to different stressing factors, including cytokines, growth factors, oxidative stress, unfolded protein response signals or A peptides. Altogether, JNKs have become a focus of screening strategies searching for new therapeutic approaches to diabetes, cancer or liver diseases. In addition, activation of JNK has been identified as a key element responsible for the regulation of apoptotic apoptosis signals and therefore, it is critical for pathological occurring cell death associated with neurodegenerative diseases and, among them, with Alzheimer's disease (AD). In addition, in vitro and in vivo studies have reported alterations of JNK pathways potentially associated with pathogenesis and neuronal death in AD. JNK’s, particularly JNK3, not only enhance Aβ production, moreover it plays a key role in the maturation and development of neurofibrillary tangles. This review aims to explain the rationale behind testing therapies based on inhibition of JNK signalling for AD in terms of current knowledge about the pathophysiology of the disease. Keeping in mind that JNK3 is specifically expressed in the brain and activated by stress-stimuli, it is possible to hypothesize that inhibition of JNK3 might be considered as a potential target for treating neurodegenerative mechanisms associated with AD.

1 January 2005 in Neuropsychologia
Verified
Journal Article
Closed access
MGMonica Garcia-Alloza
Monica Garcia-Alloza
FGFrancisco Gil-Bea
Francisco Gil-Bea
MDM. Diez-Ariza
M. Diez-Ariza
CCC.P.L.-H. Chen
C.P.L.-H. Chen
PFP.T. Francis
P.T. Francis
Maria Javier RamirezMaria Javier Ramirez
Maria Javier Ramirez

10 May 2008 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
NEN. Elizalde
N. Elizalde
FGFrancisco Gil-Bea
Francisco Gil-Bea
Maria Javier RamirezMaria Javier Ramirez
Maria Javier Ramirez
BAB. Aisa
B. Aisa
BLB. Lasheras
B. Lasheras
RTR. M. Tordera
R. M. Tordera

1 March 2013 in Neurobiology of Aging
Verified
Journal Article
Closed access
MSMaite Solas
Maite Solas
PFPaul T. Francis
Paul T. Francis
Rafael FrancoRafael Franco
Rafael Franco
Maria Javier RamirezMaria Javier Ramirez
Maria Javier Ramirez